重大事件
即時報告
8-K
2026-07-20
奧麥羅製藥完成回購1450萬美元可轉換優先票據 累計註銷3050萬美元
AI 繁中摘要
📄 Omeros Corporation（納斯達克：OMER）於 2026 年 7 月 20 日提交 8-K 表格，披露其已完成部份可轉換優先票據的回購行動。
🔹 事件重點：公司早前於 2026 年 7 月 2 日與若干 2029 年到期的 9.50% 可轉換優先票據（「票據」）持有人達成私下協議，同意在均價期結束後回購部份未償還票據。2026 年 7 月 20 日，公司完成回購本金總額約 1,450 萬美元的票據，購買總價（包含應計未付利息及其他債務）約為 2,900 萬美元。
🔹 累計回購金額：公司此前已向相同持有人回購 1,600 萬美元本金票據。連同本次操作，合共回購並註銷 3,050 萬美元本金票據。完成上述回購後，仍有約 4,030 萬美元本金票據在外流通。
💡 對投資者的潛在影響：
- 減少未來利息支出及債務負擔，有助改善資產負債表。
- 回購價格高於本金（約 2 倍），反映折價票據的溢價攤銷，短期或影響現金流。
- 剩餘票據規模縮小，可降低財務風險，但需留意公司後續融資計劃及營運現金狀況。
展開英文正文
omer20260716_8k.htm false 0001285819 0001285819 2026-07-20 2026-07-20 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 20, 2026 OMEROS CORPORATION (Exact name of Registrant as Specified in Its Charter) Washington 001-34475 91-1663741 (State or Other Jurisdiction of Incorporation) (Commission File Number) (IRS Employer Identification No.) 201 Elliott Avenue West Seattle, WA 98119 (Address of Principal Executive Offices) (Zip Code) Registrant’s Telephone Number, Including Area Code: (206) 676-5000 (Former Name or Former Address, if Changed Since Last Report) Check the appropriate box below if the Form 8‑K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below): ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities Registered Pursuant to Section 12(b) of the Act: Title of each class Trading Symbol(s) Name of each exchange on which registered Common stock, par value $0.01 per share OMER The Nasdaq Stock Market LLC Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 under the Securities Act of 1933 (17 CFR 230.405) or Rule 12b-2 under the Securities Exchange Act of 1934 (17 CFR 240.12b-2). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ Item 8.01 Other Events. As previously disclosed, on July 2, 2026, Omeros Corporation (the “Company”) entered into privately negotiated agreements with certain holders of its 9.50% Convertible Senior Notes due 2029 (the “Notes”) under which the Company agreed to repurchase a portion of the outstanding Notes following completion of an averaging period. The Company completed the repurchase of approximately $14.5 million aggregate principal amount of Notes on July 20, 2026, for a total purchase price, inclusive of accrued and unpaid interest and all other obligations, of approximately $29.0 million. The Company previously disclosed the repurchase of $16.0 million principal amount of Notes pursuant to privately negotiated agreements with the same holders referenced above. In total, the Company has repurchased and retired $30.5 million aggregate principal amount of Notes. Approximately $40.3 million principal amount of Notes remains outstanding following completion of the repurchases. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. OMEROS CORPORATION Date: July 20, 2026 By: /s/ Gregory A. Demopulos Gregory A. Demopulos, M.D. President, Chief Executive Officer and Chairman of the Board of Directors